Ascertainment and Verification of End-Stage Renal Disease and End-Stage Liver Disease in the North American AIDS Cohort Collaboration on Research and Design

Abstract EN

The burden of HIV disease has shifted from traditional AIDS-defining illnesses to serious non-AIDS-defining comorbid conditions.

Research aimed at improving HIV-related comorbid disease outcomes requires well-defined, verified clinical endpoints.

We developed methods to ascertain and verify end-stage renal disease (ESRD) and end-stage liver disease (ESLD) and validated screening algorithms within the largest HIV cohort collaboration in North America (NA-ACCORD).

Individuals who screened positive among all participants in twelve cohorts enrolled between January 1996 and December 2009 underwent medical record review to verify incident ESRD or ESLD using standardized protocols.

We randomly sampled 6% of contributing cohorts to determine the sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) of ESLD and ESRD screening algorithms in a validation subcohort.

Among 43,433 patients screened for ESRD, 822 screened positive of which 620 met clinical criteria for ESRD.

The algorithm had 100% sensitivity, 99% specificity, 82% PPV, and 100% NPV for ESRD.

Among 41,463 patients screened for ESLD, 2,024 screened positive of which 645 met diagnostic criteria for ESLD.

The algorithm had 100% sensitivity, 95% specificity, 27% PPV, and 100% NPV for ESLD.

Our methods proved robust for ascertainment of ESRD and ESLD in persons infected with HIV.